Present Address: Laboratoriet för Klinisk kemi och Transfusionsmedicin, Skene Lasarett Varbergsvägen, 50511 81, Skene, Sweden Abstract Purpose: The purpose is to address the problem in magnetic resonance imaging (MRI) of contrast agent dilution. Procedures: In situ magnetic labeling of cells and MRI were used to assess distribution and growth of human hepatic stem cells (hHpSCs) transplanted into severe combined immunodeficiency (SCID)/non-obese diabetic (NOD) mice. It was done with commercially available magnetic microbeads coupled to an antibody to a surface antigen, epithelial cell adhesion molecule (EpCAM), uniquely expressed in the liver by hepatic progenitors. Results: We validated the microbead connection to cells and related MRI data to optical microscopy observations in order to develop a means to quantitatively estimate cell numbers in the aggregates detected. Cell counts of hHpSCs at different times post-transplantation revealed quantifiable evidence of cell engraftment and expansion. Conclusions: This magnetic labeling methodology can be used with any antibody coupled to a magnetic particle to target any surface antigen that distinguishes transplanted cells from host cells, thus facilitating studies that define methods and strategies for clinical cell therapy programs.
Introduction
T he paucity of livers available for orthotopic liver transplantation results in an increased interest in liver cell therapies in which suspensions of cells are injected into the livers of patients with liver failure [1] [2] [3] . Cells obtained from a single donated liver are used to treat multiple patients. Furthermore, the surgical procedures for cell therapies are less drastic, potentially safer, and more economical than whole organ transplantation. As part of those investigations, tracking methods are being explored for ways to follow what happens to the donor cells after transplantation, both in terms of their final location within the host and whether they demonstrate expansion within the host tissues.
Labeling and noninvasive detection of transplanted cells are areas of active research in molecular imaging involving a variety of imaging modalities. For short-term (i.e., several days to a few weeks) monitoring, cells pre-labeled with, for example, superparamagnetic iron oxide (SPIO)-contrast agents can be readily detected using magnetic resonance imaging (MRI) [4, 5] . The challenge of the pre-labeling approach for all modalities is that the labels invariably fade over time as their concentrations become diluted after each cell proliferation cycle. Alternative approaches, ideally those that allow cells of interest and imaging labels to be transplanted or administered separately, are needed for long-term cell tracking. A promising method has been developed for positron emission tomography (PET) using a combination of cells transfected with herpes simplex virus thymidine kinase and a special class of 18 F radiolabels [6] [7] [8] . However, techniques for post-transplantation labeling and detection remain elusive for MRI, despite that the modality offers the advantages of better spatial resolution and involves non-ionizing radiation.
Another challenge for all cell therapies from solid organs is that transplantation is done by a vascular route, the current method of choice, and the cell populations not only engraft partially into the target tissue but also distribute to other tissues. In the case of liver cell therapies, the most common ectopic sites are the lungs and kidneys [2, 9, 10] . This general issue is a major factor in ongoing debates as to whether liver cell therapies should be done with mature parenchymal cells or with hepatic progenitors [2, 11, 12] . The mature cells yield higher engraftment, since they are larger (~or 920 μm), have a propensity for clumping leading to aggregates of cells lodged within the sinusoids of the liver or in any tissue to which they go, and the aggregates facilitate engraftment. The disadvantages are that the clumps increase the risk of life-threatening emboli formation, especially in the lungs; the cells are highly immunogenic resulting in the need for immunosuppressive therapy; and the effects of the donor cells can be transient. By contrast subpopulations of hepatic progenitors are (1) small (7-12 μm), (2) have lower engraftment (G5%) if injected by the portal vein and higher engraftment (similar to that of mature cells) when injected into the hepatic artery, (3) rarely lead to emboli, (4) have minimal or negligible immunogenicity, and (5) the cells that do engraft into the liver offer long-term effects for the patient [3] . The debates are spurring investigations to identify better methods for transplantation, methods that can be assessed most easily if there is the ability to track the cells after transplantation.
We are focused on developing forms of liver cell therapies utilizing human hepatic progenitors, particularly human hepatic stem cells (hHpSCs) that are small (7-9 μm in diameter) and give rise to human hepatoblasts (hHBs, 10-12 μm in diameter) that in turn mature into the hepatocytic and biliary cellular lineages of the liver. The hHpSCs can be immunoselected from cell suspensions of fetal and postnatal livers of all donor ages as cells positive for both epithelial cell adhesion molecule (EpCAM) and neural cell adhesion molecule (NCAM) [13, 14] . The hHpSCs have been extensively characterized and conditions identified for their ex vivo expansion and differentiation [14] [15] [16] [17] [18] [19] . In addition to EpCAM and NCAM, the hHpSCs express E-cadherin, CD133/1, albumin, Sonic and Indian hedgehog proteins and their receptor, patched, cytokeratins (CK 8, 18, and 19), telomerase protein within the nucleus [17] have a metabolomics profile typical of stem cells [20] and are negative for α-fetoprotein (AFP), intercellular adhesion molecule (ICAM-1), and all forms tested of P450s. They are negative also for markers of hemopoietic cells (CD34, CD38, CD14, CD45, CD90, glycophorin A), endothelial cells (CD31, von Willebrand factor, VEGFr, CD146) and mesenchymal cells (desmin, α-smooth muscle actin, vitamin A, CD146) [13, 19] .
Transplantation of hHpSCs must include strategies for tracking them in vivo to (1) monitor cells at a designated site, (2) define rigorously the cell seeding densities, (3) track cell integration within the host tissues, and (4) assess cell proliferation of the transplanted cells within the liver. Here, we present a method for in vivo cell MRI tracking enabling noninvasive monitoring of the hHpSCs after transplantation. The methods identified consist of marking the cells, pre-and/or post-cell transplantation, with magnetic nanoparticles coupled to a surface antigen antibody that can distinguish transplanted cells from host cells. The transplanted hHpSCs were detected by MRI signals that were confirmed and calibrated against in vitro signal responses utilizing established cell spheroid aggregates with known cell numbers. A major novelty of the current study is the detection of transplanted cells with MRI contrast agents administered after transplantation, which paves the way for monitoring cell distribution and growth in long-term studies.
Materials and Methods

Human Fetal Livers
Livers from human fetuses between 16 and 20 weeks gestational age were obtained from an accredited agency (ABR) within 18 h of isolation and arrived in a medium, Kubota's medium (KM), found effective for hepatic progenitors [21] , supplemented with 5% fetal bovine serum, and maintained at 4°C.
Media and Solutions
All media and buffers were sterile-filtered (0.22-μm filter) and kept in the dark at 4°C before use. RPMI-1640 (Gibco/Invitrogen, Carlsbad, CA) was used as the basal medium for cultures. All reagents except those noted were obtained from Sigma (St. Louis, MO).
Serum-free KM was designed originally for rat hepatoblasts (rHBs) [21] and now has been found effective for hHpSCs [13, 14, 22] . It consists of any basal medium (here being RPMI 1640) with no copper, low calcium (0.3 mM), 10 −9 M selenium, 0.1% BSA or 0.1% HSA, 4.5 mM nicotinamide, 0.1 nM zinc sulfate heptahydrate, 10 −8 M hydrocortisone, 5 μg/mL transferrin/Fe, 5 μg/mL insulin, 10 μg/mL high density lipoprotein, and a mixture of free fatty acids that are added bound to purified human serum albumin. Details of its preparations are given in a recent methods review [23] .
Preparation of Cell Suspensions and of Cultures
Cell Preparations Cell suspensions of human fetal livers were prepared as described previously [13, 23] . Culture selection of hHpSCs was done as described previously [23] . Approximately 3×10 5 cells were plated onto a 10-cm culture dish (cat# 08-771-24; Fisher Scientific, Pittsburgh, PA) and in KM with 5% fetal bovine serum, FBS (cat# 26140-079, GIBCO, Carlsbad, CA). After the cells attached (within a few hours), the medium was changed to serum-free KM, and further medium changes with serum-free KM occurred every 3 days. Colonies were formed within 3-5 days and were observed for up to 3 months. Each colony is comprised of hHpSCs to which angioblasts are closely associated; the angioblasts gave rise to hepatic stellate cell and endothelial cell precursors found just outside the perimeter of the colony [13, 14, 24] . For the experiments, hHpSC colonies were picked by hand after 14-18 days using an inverted microscope (1X-FLAIII; Olympus, Japan and Melville, NY). Representative hHpSC colonies are shown in Fig. 1d -f.
Mice and Rats
C57Bl/6 severe combined immunodeficiency (SCID)/non-obese diabetic (NOD) mice were purchased from Jackson Laboratories (Bar Harbor, ME) and Sprague-Dawley rats from Charles River (Raleigh, NC). The mice were housed in a barrier facility and the rats in a standard animal room on the campus of the University of North Carolina-Chapel Hill (UNC-CH), Chapel Hill, NC. Animals received care according to the Division of Laboratory Animal Medicine, UNC-CH guidelines approved by American Association for Laboratory Animal Care.
Transplantation of hHpSCs into Immunocompromised Hosts
Animals were anesthetized with 40-85 mg/kg pentobarbital injected intraperitoneally (IP) and treated after the "toe pinch" reflex displayed a pain-free state. For survival studies and posttransplantation, animals were given analgesics, Ketamine HCL (100 mg/kg) mixed with Xylazine (5-16 mg/kg), IP, and warmed under a heat lamp for 15 min to assist in post-surgery recovery. An additional dose of Ketamine HCl and Xylazine IM was administered 8 h later. For studies not requiring survival of the animals, the animals were anesthetized by IP injection and monitored until the toe pinch reflex displayed them to be pain-free. They were then immediately exsanguinated, and liver, lungs, kidneys, and other tissues were dissected free and fixed with paraformaldehyde. The abdominal cavity was opened; the aorta was cannulated and then clamped; and the portal vein was severed. Then, 60 mL of 1× phosphate buffered saline (PBS) was retro-flowed through the liver at 8 mL/min to clear the liver of red blood cells before proceeding as described below.
Tissue Procurement from Transplanted Mice
After euthanasia, the liver was removed, cut into 2 mm 3 portions, and saturated in 30% sucrose in 1× PBS. Tissues were then embedded in Tissue-Tek O.C.T. Compound (Sakura, Hayward, CA), snap frozen utilizing a 100% ethanol bath surrounded by liquid nitrogen, prepared for 5-μm-thick frozen sections, and the sections mounted on tissue culture slides. Routine examinations were made in some sections stained with hematoxylin-eosin (H&E) and with the others for immunohistochemistry. 
Immunohistochemistry: Paraffin Embedded Tissues
Serial sections (5 μm thick) were prepared of formalin-fixed, paraffin-embedded livers from mice that were transplanted with hHpSCs or from controls not transplanted with cells. The sections were incubated twice in PBS with 0.3% Triton X-100 for 10 min and then in 0.3% hydrogen peroxide solution in order to block endogenous peroxidase activity. The sections were then blocked with serum and treated with an avidin-biotin blocking kit. This kit and associated reagents for avidin-biotin staining are all from Vector Laboratories (Burlingame, CA). The blocking was used to inhibit nonspecific binding in the tissue and then incubated with primary antibody overnight at 4°C. Protease digestion using the Auto/Zyme Reagent Set (Biomeda, Foster City, CA) was employed for CK-19 staining before blocking with serum. Sections were then incubated with biotinylated secondary antibody and ABC reagents of the Vectastain Elite Universal ABC kit according to the manufacturer's instructions. The secondary antibody was detected using the avidin-biotin-peroxidase method with 3,3′-diaminobenzidine as the substrate. Negative controls were performed by omitting the primary antibody and/or using isotype control antibodies. These controls revealed minimal or no background staining (Fig. 1b) .
Immunochemistry: Frozen Sections
Sections were fixed in 50/50 acetone-methanol for 2 min, washed in PBS, and blocked with 10% goat serum for 45 min. The sections were then exposed to primary conjugated human antibody at room temperature for 1-h. Details of antibody concentrations are listed in Table 1 .
Magnetic Beads
Magnetic bead immunoselection technologies make use of magnetic beads coupled to a specific antigen antibody that are presented to cells [4] . In this study, HEA-125 antibodies to EpCAM coupled to magnetic iron microbeads were obtained from Miltenyi Biotech (Bergisch Gladbach, Germany, recently cataloged as CD326 Microbead). The EpCAM antibody microbead has an overall diameter of 50-100 nm, well within viral particle size magnitudes of G200 nm, and is a surfacetagging agent that can be endocytosed into the cell. Since the agent is a magnetic label, it is expected to enhance T2 and T2* relaxations and lead to hypointensity or signal voids in MR spin echo or gradient echo scans.
Labeling the Cells with EpCAM Magnetic Microbeads
Cells were exposed to an EpCAM microbead concentration of 10 μL EpCAM antibody/microbead per 10 7 cells in 100 μL buffer In all of them the nucleus is stained with DAPI (blue). d Digital interference contrast images with DAPI staining providing a higher magnification of an hHpSCs colony; e Immunohistochemistry of the hHpSC colony for EpCAM (green); f Immunohistochemistry of the hHpSC colony for EpCAM (green) and NCAM (red). 
Aggregates of hHpSCs
Three-dimensional (3-D) aggregates of hHpSCs were generated from cell stock suspensions by placing cells in culture dishes containing KM and by placing the dishes on Thermolyne Orbital Rotomix M71735 rocker platforms (Krackeler, Scientific, Albany, NY). Platforms were placed inside an incubator (37°C, 5% CO 2 ) and rockers swayed at 10 rpm. Small aggregates were removed after a 10-min duration, while larger aggregates were generated over 90-min intervals. The radius, diameter, and area of the harvested cell aggregates were determined with hematocytometer and phase contrast imaging. Area measurements and volumetric extrapolations were made assuming a single hHpSC has a radius of 8 μm, and the descendents of hHpSCs, the hHBs, have a single cell radius of~11 μm, findings supported in direct measurements done in prior studies [13] [14] [15] . 
Pre-transplantation MRI
Validation of MRI Detectability of Labeled Cells In Situ
To determine whether labeled cells can be detected in situ, labeled and unlabeled hHpSCs were transplanted directly into livers of SpragueDawley rats and then immediately imaged. Labeled or unlabeled hHpSCs (n=~2E6) suspended in 70 μL of serum-free KM were transplanted into the liver through portal vein catheterization. Since the livers were to be isolated for imaging (to enhance the signal strength), a potential complication arises from the paramagnetic property of deoxygenated blood. Consequently, the liver was perfused with 4% paraformaldehyde containing Magnevist, gadopentetate dimeglumine (Berlex Imaging, Montville, NJ) at a 20:1 liquid suspension to remove red blood cells and enhance T1 imaging. The organ was then excised and kept in 4% paraformaldehyde. For MRI, the isolated livers were placed on a 3.0-cm-diameter surface radio frequency (RF) coil. 
Post-Transplantation Labeling and MRI
For cell transplantation, 2E6 labeled or unlabeled hHpSCs suspended in 70 μL KM were transplanted into the spleens of SCID/NOD mice by exteriorizing a small segment of spleen from the mouse's left lateral side. The cells were injected intrasplenically using a gastight syringe and RN series needles (Hamilton, cat #1710 and #80427). Once transplanted, the spleen was repositioned within the peritoneum, and the site sutured closed. In the study, 16 animals were used and divided into four groups (each with n=4): (1) sham studies, in which the animals were subjected to mock surgery; (2) controls injected with microbeads but without cells; (3) controls transplanted with unlabeled cells; and (4) mice transplanted with labeled cells. On days 6 and 18, and for groups 1, 2, and 3, 15 μL of HEA-125 (EpCAM) microbeads were mixed with 85 μL PBS solution and infused into the circulatory blood stream via mouse tail vein injection. Eight hours post-infusion, the mice were sacrificed and perfusion fixed via left ventricle cardiac cannulation in preparation for MRI. In group 4, because cells were pre-labeled prior to transplantation, mice were not exposed to the 85 μL PBS-EpCAM microbead solution, but they were fixed and MR imaged at the same times as groups 1, 2, and 3. For MR imaging, animals were positioned within a 4.0-cm-diameter birdcage RF coil for tissue investigations and analyzed as described above for the isolated livers. For confirmation, the MRI images were of transplanted human cells, the livers were prepared for immunohistochemical analyses as described above.
Data Analyses
All experiments were repeated with suspensions of hHpSCs from at least three independent tissue isolations, with triplicate measurements per experiment. All data sets were plotted using Sigma Plot (SPSS Science) or Microsoft Excel (Microsoft, Redmond, WA), where each graph's error bars indicate ±one standard deviation.
Results
EpCAM is a Surface Marker on hHpSCs
Transplantation of EpCAM+ cells into SCID/NOD mice resulted initially in cells clustered near the central veins and detectable with antibodies to human albumin (Fig. 1a) . The hHpSCs do not express AFP [13] , but after transplantation into the livers of the murine hosts, they expanded and matured within a few days to hHBs with strong expression of human AFP (Fig. 1c) . In studies reported elsewhere, longer periods of time in vivo resulted in fully mature human liver cells [13] . Fig. 1b is an image of a liver section stained with an isotope control antibody.
In cultures, the hHpSCs undergo clonogenic expansion on plastic and in serum-free KM (Fig. 1d-f) . The hHpSCs strongly express EpCAM (green labeling in Fig. 1e and f) and also NCAM (red staining of cells in Fig. 1f ). The nuclei are visible by staining with 4′,6-diamidino-2-phenylindole (DAPI; Fig. 1d-f) .
Labeling of hHpSCs with Magnetic Microbeads Tagged with EpCAM Antibody
Magnetic beads are available in varying sizes, but those found especially useful are very small beads that are the size of viral particles (50-100 nm). Access of such particles to tissues will vary with the three known categories of capillaries comprised of (1) continuous capillaries (skeletal muscle, heart, skin), (2) fenestrated capillaries (intestinal mucosa, endocrine and exocrine glands, kidney), and (3) discontinuous capillaries (reticulo-endothelial tissues including the liver, bone marrow, and spleen). The width of inter-endothelial gaps (also called clefts) in continuous capillaries are 20-60Å and accommodate only ions and water; those in fenestrated capillaries are~60-80 nm and allow small molecules and some proteins; and those in reticulo-endothelial cells are 30-40 μm and allow hemopoietic cells and large molecules. In addition, in all three categories, there are endothelial cell pores, called "fenestrae," of two sizes, the larger one being 200-300Å and that accommodate transport of molecules of varying size across the endothelial cell [25] .
Schematics depicting cell-bead-MRI relations are shown in Fig. 2 on which is a representative bead (Fig. 2a) and its attachment to cells via antibodies (Fig. 2b) .
The internalization and surface attachment of HEA-125 (EpCAM) microbeads into/onto hHpSCs was confirmed by TEM and SEM analyses on cultured cells (Fig. 3) . Control images for both TEM and SEM consisted of unlabeled cells. The experimental groups consisted of hHpSCs labeled with EpCAM microbeads. The high magnification (2,000×) TEM micrograph shown in Fig. 3a displays a heterogeneous distribution of 80-nm-diameter glycogen particles throughout the cell's interior, seen as gray and black dotted specks. The detail Fig. 3b (31,500× image) further displays the spheroid structure of glycogen. Glycogen's dark contrast and size can cause it to interfere with recognition of microbeadlabeled cells and single contrast agents 50-100 nm in size. For contrast-labeled cells, as shown in Fig. 3c and d , glycogen is again seen within the cells interior. As shown in both figures, several large particles having~222-nm diameters are observed in the cell's interior. These particles are much larger than those for glycogen or individual EpCAM microbeads (e.g., 50 nmGxG100 nm) and are due to aggregation of microbeads.
Further characterization of EpCAM microbeads on cells is shown with the SEM micrographs in Fig. 3e-i . A SEM control (Fig. 3e) illustrates two hHpSCs in close physical contact and without labeling with EpCAM microbeads. The cells' surfaces are fairly smooth and absent of irregularities caused by microbead surface attachments. Contrastingly, Fig. 3f shows a contrast-labeled cell with large numbers of EpCAM microbeads on the left lateral cell surface (arrows). Further illustrations of these microbeads are shown in Fig. 3g -i in which cells are labeled with EpCAM microbeads and viewed at increasing image magnifications. Fig. 3g displays large clumps of microbead aggregates. Fig. 3h illustrates enhanced microbead detail with many intertwined beads connected to form a "web mesh" on the cell's surface. Fig. 3i illustrates EpCAM microbeads clustered on cell surfaces with detectable diameters ranging from 100 nm (smallest) to 500 nm (medium) to 4166 nm (large) magnitudes.
To confirm that the imaged particles are the EpCAM magnetic microbeads, EDX imaging system was used to provide a "snapshot" view of the microbeads atomic structure, as displayed in the line graph in Fig. 3j . As the graph shows, multiple peaks over a 0-10 keV range are distinctly labeled. The peak for Fek α iron (Fe), as determined by K-shell valance electron removal (k α ) at 6.3 keV, indicates that the microbeads contain iron. Other components include magnesium (Mg), aluminum (Al), silicone (Si), and silver (Ag). The white specks in Fig. 3j are illustrative of EDX signals associated with microbead-labeled cultured cells.
MRI of hHpSCs in Agarose Gels
Representative MR images of agarose-embedded cells, with and without labeling, are shown in Fig. 4 , including (1) gel only without cells, (2) gel with unlabeled cells, and (3) gels with labeled cell aggregates. For the agarose-only control (Fig. 4a) , the image depicts a relatively homogeneous light gray background. Few MR signal irregularities were observable, including background intensity non-uniformity due to RF coil magnetic field inhomogeneity (e.g., lower quarter of the FOV) and intensity voids arising from large (e.g., lower left side of the dish marked by ⇓) and miniscule air bubbles (↑ or ↓) that developed during agarose gelation. The MRI appearance of the agarose gel containing unlabeled cell aggregates (Fig. 4b) is similar to that of the agarose-only control. In contrast, agarose gel containing EpCAM nanoparticle-labeled cell aggregates (Fig. 4c) has conspicuous large clusters of signal voids of varying sizes, attributed to cell aggregates of varying sizes that are labeled with paramagnetic iron oxide contrast agents.
Quantitative Spheroid Formations Analyzed by Microscopy and MRI Normalizations
To provide a basis for estimating the number of cells in aggregates detected in MR images, the aggregate radii were measured by microscopy using a hemocytometer grid (200-μm grid), categorized with respect to appropriate headings (e.g., small, medium, and large) and compared against MR signals from labeled cells (Fig. 5) . Some measurement variability is acknowledged as individual cell radii are heterogeneous in size with variations being associated with cell sourcing, microscopy optics, and image overlay thresholds. The number of cells in selected aggregates was determined by microscopy and correlated to the aggregate volumes estimated from their radii, assuming a spherical shape. For example, a cell count of 120 was found for an aggregate of 33-μm radius, or 1.5E5-μm 3 volume. Linear regression of the cell count versus aggregate volume yielded the relationship:
where N is the cell count, and V microscopy is the aggregate volume in μm 3 . Moreover, the radii of some cell aggregates measured from microscopy and MR images were correlated (Fig. 6 ) resulting in the relationship:
with r MRI and r microscopy representing the MRI and microscopy measured cell aggregate radii, respectively. The cell aggregate radii showed a very strong correlation, with correlation r 2 =0.99. Not surprisingly, the cell aggregates appeared larger (64% in this case) in MRI than in actuality, since the influence of the magnetic beads that give rise to the MRI contrast extends beyond their physical boundary. Based on Eqs. 1 and 2, the cell count N in terms of MRIobserved aggregate radius r MRI is estimated to be:
Alternatively, for instances when the cell aggregates are clearly non-spherical, Eq. 2 is used to convert Eq. 1 into:
where V MRI is the volume of the MRI region of interest. Equations 3 and 4 were used to compute directly the cell count based on MRI observed aggregate size in all subsequent analysis, with the caveat that it represents only a first-order approximation, given all factors and assumptions involved.
MRI Detection and Quantification of Labeled Cells in Situ
MR images of labeled cells injected into whole livers in three animals are shown in Fig. 7 , which clearly demonstrates the detectability of the labeled cells. Fig. 7a1 illustrates two liver lobes with intensity voids corresponding to aggregates of labeled cells throughout the tissues. For analysis, a polygonal region of interest was segmented on the region containing relatively high concentration of signal voids. The intensity of the region was inverted and then thresholded to obtain a binary image that better shows the locations and sizes of the labeled cell aggregates (Fig. 7a2) . Comparable MRI and cell aggregate binary images obtained for the other two animals are shown in 3. TEM (a-d) , scanning electron microscopy (SEM, e-i), and emission-dispersive X-ray (EDX, line graph and j) displaying human cells labeled with HEA-125 antibodies coupled to magnetic microbeads (Miltenyi). a-d Ability to detect the microbeads and to distinguish them from glycogen particles (small arrows) occurs with aggregates yielding a size above 200 μm (large arrows). e SEM of hHpSCs that is not labeled with the beads. f-i SEM of hHpSCs labeled with the beads (arrows denote the beads). j The line graph is from EDX analyses and shows that the beads on the cells contain the elements known to be in the EpCAM microbeads, notably iron.
Post-Transplantation Cell Labeling, Detection, and Quantification
Selected 2-D MR image slices of the post-transplantation celllabeling study are shown in Fig. 8 . For the controls, Fig. 8a -c illustrate adequately perfused liver lobes that appear as homogeneous backgrounds except for the hyperintense branching pathways near the liver center that correspond to the hepatic sinusoids. Intensity voids that signify labeled cell aggregates are clearly absent. This confirms the lack of contrast from the microbeads in each of the three control groups, which include hosts not injected with human cells, hosts injected only with microbeads, and hosts injected with unlabeled hHpSCs. Fig. 8d and e shows representative MRI images of hosts originally injected with unlabeled hHpSCs but subsequently were given magnetic microbeads on days 6 and 18, respectively, after transplantation. At least two and five hypointense foci that indicate the presence of hHpSC aggregates can be detected in the days 6 and 18 MR image slices, respectively. Although the relative locations of cell aggregates are not conspicuous in the day 6 image slice, those in the day 18 image slice are clearly located near large sinusoidal pathways of the liver, which is consistent with the fact that cells were transplanted into the liver via the portal vein and must migrate through sinusoidal pathways before integrating into the liver tissue.
Examinations of all image slices obtained for the hosts labeled at days 6 and 18 detected the presence of a total of four and seven hHpSC aggregates, respectively. Using the quantification technique described above, the cell counts for the aggregates found in sites 1 and 2 of the day 6 image slice shown in Fig. 8d are approximately 1065 and 128, respectively. The two additional aggregates detected were determined to have approximately 289 and 527 cells. Similarly, the cell counts in sites 1-5 of the day 18 image slice ( Fig. 8e) 3 cells. Although these cell counts are estimates, the fact that more aggregates are found and that most aggregates have markedly higher cell count in day 18 than in day 6 are indicative of post-transplantation cell proliferation.
Discussion
We demonstrated a novel method for MRI tracking of transplanted human hepatic stem/progenitors (hHpSCs and hHBs) by labeling the cells in situ with magnetic microbeads coupled to an antibody binding to a surface antigen on the transplanted cells. The first antigen used to establish the technique has been human EpCAM, found in human livers uniquely on hHpSCs, hHBs and other hepatic progenitors [13, 14] , on liver cancer stem cells that are transformants of a subpopulation(s) of the hepatic stem/progenitors [26] , and on proliferating epithelial cells in other tissues [27] [28] [29] . The method is applicable to any surface antigen for which antibody magnetic microbeads are available. Existing methods for tracking transplanted cells are either nonspecific, require marking the cells prior to transplantation, are effective only for short-term studies, or potentially can harm the cells. One of the most established techniques is to mark the cells with magnetic beads (particles, nanoshells) that become incorporated into cells by endocytosis [4, [30] [31] [32] [33] . The ability to mark the cells is dependent on their propensity to endocytose the magnetic beads or nanoshells. The uptake of magnetic particles can be made more efficient by the use of electroporation [34] . However, all labeling strategies dependent on endocytosis offer little specificity as to which cells become marked. Similar problems occur for cells marked by perfluorocarbon nanobeacons [35] and with TAT-peptide derivatized nanoparticles [5] or with contrast agents [4, 30, 36] . Stable labeling of a specific cell population, such as by transfection of a gene, is highly successful and widely used for experimental studies [36, 37] , but is not suitable for clinical programs given that transfected cells can give rise to tumors depending on the integration site [38, 39] . The newest strategies reported are ones in which magnetic resonance spectroscopy are focused on metabolomic profiling of unique subpopulations, such as stem/progenitor cells [40] , and offer a way to monitor endogenous and transplanted cells via unique metabolomic features detectable by MR spectroscopy [20, 41] . This approach does not distinguish transplanted versus endogenous cells unless the transplanted cells are in a tissue site distinct from that of the endogenous cellular subpopulations.
Contrast agents, such as gadolinium-diethylenetriamene pentaacetate (DTPA) complex or SPIO-based colloids, facilitate visibility and display more intense MR signals, but these also do not have specificity [36, 42, 43] . Signal agents can range from iron metabolites (e.g., deoxygenated blood) to paramagnetic structures (copper, manganese) and to superparamagnetic structures (iron oxide) that can target receptors through iron oxide surface modifications [43] . Each agent modifies either T1, T2, or T2* relaxation decays for signal contrast. The use of such nonspecific labeling has proven effective but limiting, because cells of interest are isolated, ex vivo labeled, transplanted, and then imaged before contrast labels detach. Detachment can be either by physical dislodgement or by chemical secretion. Viable cells strive for homeostasis and efficiently remove foreign particles from their microenvironments obviating the use of this approach for long-term studies.
We demonstrate a method that can be used in experimental and clinical programs and that can identify cells that can be labeled before or after transplantation. Moreover, transplanted cells can be monitored in the same host again and again by injection of the label just prior to MR imaging (Fig. 8) negating the need for long-term contrast attachment and eliminating uncertainties of contrast decay. In vivo labeling with antibodies to specific surface markers and tagged to magnetic microbeads makes possible the imaging of specific subpopulations of cells with defined antigenic profiles.
Being able to visualize the target population against the background of other cells will vary with the antigen chosen. We were able to limit the background by using xenogeneic transplants of human hepatic progenitors into immunocompromised murine hosts and using an antigen, EpCAM, expressed only by the human cells [13, 14, 19] . Targeting EpCAM should work also for transplantation into human livers, given that the only cells in the liver that express it are hHpSCs and hHBs, both located adjacent to the portal triads of the liver acinus. These progenitor subpopulations constitute a small percentage (G1-2%) of the parenchymal cell populations in pediatric and adult livers. Achieving visibility of a target population by MRI will be straightforward if the target population is antigenically distinct from the surrounding cells such as what would occur with cancer cells, other types of mutated cells, or cells damaged by disease or other insults [26, 27, 44] .
The EpCAM microbeads, with diameters smaller than viruses (G200 nm), were able to traverse through the host's circulatory system and capillary beds to adhere to transplanted cells expressing the antigen (Fig. 8) . Immunohistochemistry to detect human-specific proteins in sections of the livers confirmed the MRI findings (Fig. 1) . At day 18, labeled aggregates were found near sinusoids (Fig. 8) . In vivo MR comparisons between days 6 and 18 signals illustrate cell growth as day 18 images confirm up to 12 times more cells than on day 6.
Cell therapies are becoming medical treatment options to support patients with diseased organs or to assist with tissue regeneration. However, to assess more rigorously the potential of cell therapies and of any particular method of transplantation, it is necessary to label specific cell types and non-invasively track cells after inoculation and to follow the location and expansion of the cells thereafter. In this work, labeling of human hepatic progenitors has been verified by in vitro, ex vivo, and in vivo MR signal patterns and correlated with in vivo responses for up to 18 days. These imaging studies confirm in vivo cell tracking of transplanted human hepatic cells is plausible and is a strategic method that can be used to improve methods for transplantation for any form of cell therapy including stem cell therapies.
An alternative use for the method is to diagnose and to follow patients with primary or metastatic tumors, now known to be comprised of mutated stem/progenitor populations with antigenic profiles distinct from those of mature cells [26, 44] . Antigens found on the tumors can be targeted with an antibody bound to microbeads and followed by patient imaging.
